Identification of Biomarkers in Subjects With Coronary Syndrome (PLAQUE Study)
Unknown statusNCT06103357
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The study will to test the levels of innovative biomarkers, such as miRNAs, in the blood of subjects underwent to angioplasty procedure according to standard clinical practice.
Study details
- Official title
- Identification of Innovative Circulating and Cellular Biomarkers in Subjects With Acute and Chronic Coronary Syndrome (PLAQUE Study)
- Conditions
- Coronary Syndrome
- Interventions
- Other: blood sample collection
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
- Collaborators
- Ministry of Health, Italy
- Start date
- 2023-03-06
- Primary completion
- 2024-04-30
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Italy
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Clinical indication for the PCI procedure according to the latest ESC (European Society of Cardiology) Guidelines * Coronary stenosis treated with angioplasty must be located in the proximal segments of the three main vessels: IVA, CX and CD * The vessels must have a diameter of their mid-distal section ≥ 3 mm * Patients with NSTEMI ACS and clinical indication with favorable anatomy for coronary angioplasty, also called percutaneous coronary intervention (PCI), (for the ACS group) * Patients with clinically incipient SCC with stable angina (or significant anginal equivalents) and clinical indication with favorable anatomy for PCI (for the SCC group) Exclusion Criteria: * Contraindications to anticoagulant/antiplatelet therapy * Extensive calcifications and/or tortuosity of the major epicardial segments * Evidence of thrombotic occupation * Patients with hemodynamic instability * Patients with EF (ejection fraction) \< 35% * Patients with severe chronic renal failure (e-GFR \< 30 mL/min)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06103357